凝固のパラメータに対するカルバマゼピンとレベチラセタムの作用: プロトロンビン時間,活性化された部分血栓形成時間,D- ダイマー,および線維素濃度
Jiaohui Li1, Chengyun Zhong1, Guanji Bian2
1Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Taizhou Branch, Department of Neurology, Taizhou, Zhejiang Province, China.
Journal of medical biochemistry
|August 21, 2025
まとめ
カーバマゼピンは,レベチラセタムよりも凝固検査に有意な影響を及ぼしますが,どちらも部分発作のを効果的に制御します. レベチラセタムは,血液の凝固に軽い効果を発揮する.
科学分野:
- 神経科学
- 薬理学について
- 血液学
背景:
- 発作は一般的な神経疾患で 効果的な治療法が必要である.
- 抗薬が凝固に与える影響を評価することは,患者の安全のために極めて重要です.
研究 の 目的:
- カルバマゼピンとレベチラセタムの単体療法の凝固パラメータに対する効果を比較する.
- これらの薬で治療された部分発作性患者の発作制御を評価する.
主な方法:
- 部分発症のエピレプシー患者89人をカルバマゼピンとレベチラセタムグループに分けました.
- 凝固検査 (プロトロンビン時間,aPTT,フィブリノゲン,D- ダイマー) と発作頻度は6ヶ月間モニタリングされた.
主要な成果:
- ベースラインと比較して,カルバマゼピンはPT,aPTT,D- ダイマー値を有意に低下させ,レベチラセタムはより顕著な変化を示した.
- フィブリノゲンは両方のグループで減少した. 発作の頻度はすべての患者で減少した.
- 2つの治療群では,発作制御率が比較可能でした.
結論:
- カルバマゼピンは凝固異常のリスクを高めますが,発作制御には有効です.
- レベチラセタムは凝固により軽い効果を持ち,発作管理の効果も同様です.
関連する概念動画
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
446
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
446
Anticoagulant Drugs: Low-Molecular-Weight Heparins
893
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
893
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.3K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.3K
Venous Thrombosis III: Interprofessional Care
22
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
22
Antiepileptic Drugs: Potassium Channel Activators
274
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
274
Antiepileptic Drugs: GABAergic Pathway Potentiators
640
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
640


